Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

Stock Information for Immunic Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immunic Inc.

Immunic to Host MS R&D Day and Participate in Investor Conferences in April
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
Immunic to Participate in Investor and Scientific Conferences in March
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
Immunic to Participate in Investor and Scientific Conferences in February
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
Immunic, Inc. Announces Private Placement of up to $240 Million

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.